Business Description
![ContraFect Corp ContraFect Corp logo](https://static.gurufocus.com/logos/0C0000ANP8.png?14)
ContraFect Corp
NAICS : 325412
SIC : 2834
ISIN : US2123261024
Description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.12 | |||||
Equity-to-Asset | -0.63 | |||||
Debt-to-Equity | -0.44 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 25.8 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 30.6 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.53 | |||||
Quick Ratio | 0.53 | |||||
Cash Ratio | 0.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.9 | |||||
Shareholder Yield % | -11827.66 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -130.28 | |||||
ROIC % | -560.14 | |||||
ROC (Joel Greenblatt) % | -1108.61 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 0.09 | |||||
EV-to-EBITDA | 0.09 | |||||
EV-to-FCF | 0.08 | |||||
Earnings Yield (Greenblatt) % | 1111.11 | |||||
FCF Yield % | -21979.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ContraFect Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -18.14 | ||
Beta | 0.16 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 4.984 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 4.984 - 4.984 | ||
Shares Outstanding (Mil) | 10.7 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ContraFect Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ContraFect Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
ContraFect Corp Frequently Asked Questions
What is ContraFect Corp(STU:22R)'s stock price today?
The current price of STU:22R is €4.98. The 52 week high of STU:22R is €4.98 and 52 week low is €4.98.
When is next earnings date of ContraFect Corp(STU:22R)?
The next earnings date of ContraFect Corp(STU:22R) is 2024-07-15 Est..
Does ContraFect Corp(STU:22R) pay dividends? If so, how much?
ContraFect Corp(STU:22R) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |